Who Paid My Doc
Ashley Schmitt
Nurse Practitioner Springfield, MN Nurse Practitioner
NPI 1184042632 CMS profile 11032853
625 N Jackson Ave, Springfield, MN 56087
General payments
$3,042
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Ashley Schmitt of Springfield, MN is reported in the CMS Open Payments database as having received $3,042 across 8 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 87th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $3,042 | 8 |
Beside peers
- Ashley Schmitt
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Ashley Schmitt were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Ashley Schmitt | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $0 | $135 | $40–$426 | $132 |
| 2022 | $0 | $152 | $48–$470 | $149 |
| 2023 | $3,042 | $166 | $54–$529 | $160 |
| 2024 | $0 | $173 | $55–$556 | $164 |
| 2025 | $0 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 87 drugsPart D claims
3,925
Drug cost
$193,758
Branded share of claims
17.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 63 | $54,034 | |
| Mounjaro Tirzepatide | Brand | 30 | $32,185 | |
| Xarelto Rivaroxaban | Brand | 26 | $19,188 | |
| Jardiance Empagliflozin | Brand | 25 | $18,974 | |
| Ozempic Semaglutide | Brand | 12 | $12,280 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 39 | $4,707 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 12 | $4,699 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 18 | $3,223 | |
| Metoprolol Succinate | Generic | 160 | $2,840 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 12 | $2,626 |
The 10 drugs with the highest cost, of 87 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 164 billing codesPaid by Medicare
$110,345
Medicare patients
252
Services billed
4,512
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 39% | |
| Arthritis | 33% | |
| Ischemic heart disease | 31% | |
| Atrial fibrillation | 26% | |
| Diabetes | 25% | |
| Heart failure | 22% | |
| Depression | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90653 | Office | 51 | 51 | $4,173 |
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 18 | 19 | $2,787 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 15 | 152 | $111 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner in Minnesota
Jill Toliver
Nurse Practitioner · Woodbury, MN
Rebecca Suess
Nurse Practitioner · Burnsville, MN
Kelly Young
Nurse Practitioner · Burnsville, MN
Kimberly Thompson
Nurse Practitioner · Rochester, MN
Janet Wilkinson
Nurse Practitioner · Mora, MN
Virginia Clementson
Nurse Practitioner · Eden Prairie, MN
Related records
Nurse Practitioner in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.